The case for & against
Bull & Bear analysis
Bullish
Boston Scientific Corporation (NYSE: BSX) is a leading global medical device manufacturer specializing in the development of innovative medical solutions for a wide range of conditions, particularly in the fields of cardiology, electrophysiology, and endoscopy. The company holds a significant market position due to its commitment to research and development, resulting in a robust pipeline of cutting-edge products. As healthcare technology continues to evolve, Boston Scientific is well-positioned to benefit from the growing demand for less invasive procedures and better patient outcomes.
Bull says
- ↑EPS expected +6.7% YoY on cardiovascular and electrophysiology innovations.
- ↑TD Cowen $56 target vs $46.95 share price implies ~19% upside.
- ↑Aging population and minimally invasive trend support long-term device demand.
- ↑Operational recovery could quickly restore WATCHMAN and EP production levels.
- ↑High ROE and strong momentum factors underline financial resilience.
- ↑Robust balance sheet and free cash flow support potential buybacks.
Bear says
- ↓Cyberattack stalled WATCHMAN and EP output, cutting 2026 EPS guidance to $3.30.
- ↓Shares plunged 49.1% YTD, underperforming sector benchmarks.
- ↓2026 EPS outlook lowered to $3.30 indicates margin and revenue pressure.
- ↓Intense competition and cost pressures threaten market share gains.
- ↓Weak profitability factors and elevated short interest weigh on sentiment.
- ↓Uncertain full operational recovery may deter investor confidence longer-term.